

10/070954

JC13 R PCT/PTO 13 MAR 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: ARKINSTALL=1

In re Application of:) Art Unit:
Stephen ARKINSTALL et al.)
I.A. No.: PCT/IB00/01380) Examiner:
Filed: September 28, 2000) Washington, D.C.
For: PHARMACEUTICALLY...) March 13, 2002
)
)

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above- identified application, and any other application relying on the filing date of the above-identified application or cross- referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[X] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

[X] B. before the mailing date of a first office action on the merits.

[] C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below).

[] i. Counsel certifies that, upon information and belief, each item of information listed herein was either

[] (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

[] (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in §1.56(c) more than three months prior to the filing of this IDS.

[] ii. A check (check no. _____) for the fee set forth in §1.17(p), presently believed to be \$180, is enclosed.

[] ii. Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in §1.17(p), presently believed to be \$180.

[] D. after (A), (B) and (C) above, but before payment of the issue fee: Applicant(s) petitions under 37 CFR §1.97(d) for consideration of this IDS. A check (check no. _____) for/ Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in §1.17(i), presently believed to be \$130 is enclosed. Counsel certifies

that, upon information and belief, each item of information listed herein was either

- [] (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- [] (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was not known to any individual designated in §1.56(c) more than three months prior to the filing of this IDS.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

[] A. Document(s) _____ is (are) deemed substantially cumulative to document(s) _____, and, in accordance with §1.98(c), only a copy of each of the latter documents is enclosed.

[] B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

Applicant(s) identifies these documents by attaching hereto copies of the forms PTO-892 and PTO-1449 from the files of the prior application(s) or a fresh PTO-1449 listing these documents, and request that they be considered and made of record in accordance with §1.98(d). Per 37 CFR §1.98(d),

copies of these documents need not be filed in this application.

[] 3. Document(s) _____ is (are) not in the English language. In accordance with §1.98(c), Applicant(s) states:

- [] An English translation of each document _____ (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application, or English-language abstract (or claim) is enclosed.
- [] A concise explanation of the relevance of document(s) _____ is found in the attached _____ search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).
- [] A concise explanation of the relevance of document(s) _____ is set forth as follows:
- [] A concise explanation of the relevance of document(s) _____ can be found on page(s) _____ of the specification.
- [] A concise explanation of document(s) _____ can be found on the attached sheet.

[X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

[X] 5. Other information being provided for the examiner's consideration follows:

10/070954

JC13 R [REDACTED] PCT/PTO 13 MAR 2002


Courtesy copy of the European Search Report

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:


Roger L. Browdy
Reg. No. 25,618

624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528

JC13 P-0'd PCT/PTO 13 MAR 2002

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

I.A. Number		PCT/IB00/01380
Filing Date		September 28, 2000
First Named Inventor		Stephen ARKINSTALL et al.
Group Art Unit		
Examiner Name		
Attorney Docket Number		ARKINSTALL=1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	5,106,983	A1	REIFF et al.	Apr. 21, 1992

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Number			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number	Kind Code ⁵ (if known)		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AB	WO	98/53814	A1	DURETTE et al.	12-03-1998
	AC	WO	97/45403	A1	HAADSMASVENSSON	12-04-1997
	AD	WO	97/30992	A1	DING et al.	08-28-1997
	AE	WO	96/30017	A1	AFONSO	10-03-1996
	AF	WO	99/21859	A1	CHEUNG et al.	05-06-1999
	AG	WO	99/16751	A1	DORSCH	04-08-1999
	AH	WO	98/53814	A1	DURETTE et al.	12-03-1998
	AI	WO	98/49188	A1	DAVIS	11-05-1998
	AJ	WO	96/06609	A1	FISHER	03-07-1996
	AK	WO	91/13872	A1	ENNIS et al.	09-19-1991
	AL	WO	96/30017	A1	AFONSO et al.	10-03-1996

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	AM	KELLY J. et al.: "Synthesis of isomeric 3-piperidinyl and 3-pyrrolidinyl benzo '5,6! Cyclohepta '1,2-bl pyridines: sulfonamido derivatives as inhibitors of Ras prenylation", BIOORG. MED. CHEM., 1998, Vol. 6, pgs. 673-686
	AN	XIE et al.: "Crystal structure of JNK3: a kinase implicated in neuronal apoptosis", Structure August 15, 1998, pgs. 983-991
	AO	YANG et al.: "Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene", NATURE, vol. 389, October 23, 1997, pgs. 865-870
	AP	YANG et al.: "Differentiation of CD4+ T CELLS TO Th1 Cells Requires MAP Kinase JNK2", Immunity, Vol. 9, 575-585, October 1998
	AQ	SABAPATHY et al.: "JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development", Current Biology 1999, vol.9, pgs. 116-125
	AR	KUMAGAE et al.: "Human c-Jun N-terminal kinase expression and activation in the nervous system", Molecular Brain Research 1999, vol. 67, pgs. 10-17

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.